Athersys, Inc. Receives Orphan Drug Designation for MultiStem in Hurler's Syndrome

Full story: BioSpace

Athersys, Inc. announced today that MultiStemA , Athersys' proprietary cell therapy, has been granted orphan drug designation by the U.S. Food and Drug Administration for the treatment of Hurler's Syndrome, also known as mucopolysaccharidosis type I or MPS-I. Hurler's Syndrome is a lysosomal storage disorder that affects approximately 1 of every ... (more)
Comments
1 - 2 of 2 Comments Last updated Jul 17, 2012
athxer

Singapore, Singapore

#1 Jul 11, 2012
any idea when a partnership for this is happening??? Don;t wish to see another dilution exercise.
athxer

Singapore, Singapore

#2 Jul 17, 2012
I'm starting to loose patience at Athersys. Whenever there's slightest bit of positive news, this damn stock will go down and remain down.

Tell me when this thread is updated: (Registration is not required)

Add to my Tracker Send me an email

Add your comments below

Characters left: 4000

Please note by submitting this form you acknowledge that you have read the Terms of Service and the comment you are posting is in compliance with such terms. Be polite. Inappropriate posts may be removed by the moderator. Send us your feedback.

Biotech Discussions

Title Updated Last By Comments
Safety Testing Of Ebola Vaccine Will Begin Soon Aug 28 Please Work 1
Findings from Lomonosov Moscow State University... Aug 27 Akrom hussain cho... 1
Maker of RevitaLash , Files Suit Against Allerg... (Aug '09) Aug 22 jazzpollard 65
Lawsuits filed over Lipitor side effects (Jun '06) Aug 21 kylie 848
Merck's shingles vaccine, Zostavax, recommended... (Jun '08) Aug 18 Susanna 75
40 percent of Americans will develop diabetes Aug 13 humanSpirit 1
Robin Williams' suicide: How to get help for su... Aug 12 Big mike 2
•••
Enter and win $5000
•••

Biotech People Search

Addresses and phone numbers for FREE

•••